DARE News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

DA

Mkt Cap

$14.1M

Volume

76.94K

Next Earnings

November 12th

Loading chart

DA

DAREDare Bioscience, Inc. Common Stock

DARE

Pay with—

Available Balance0.00

DA

Mkt Cap

$14.3M

Volume

76.94K

Next Earnings

November 12th

Chart Financials Earnings News About Insider Filings

Daré Bioscience Posts Narrower Q2 LossDaré Bioscience reported a Q2 2025 loss with negative revenue, but demonstrated progress in women's health product pipeline, including Sildenafil Cream and Ovaprene, while managing tight liquidity through strategic partnerships and grant funding.The Motley Fool · Aug 14, 2025

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the BarDaré Bioscience announced a webinar on August 6, 2025, introducing DARE to PLAY™, a novel sildenafil cream designed to improve female sexual arousal, targeting prescription availability in Q4 2025.GlobeNewswire Inc. · Jul 21, 2025

Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%Daré Bioscience announced positive findings from a Phase 2b study of its investigational topical cream Sildenafil Cream, 3.6% for the treatment of female sexual arousal disorder (FSAD). The study showed consistent results from patient-reported outcome measures, regardless of recall period, supporting the use of longer recall intervals which are less burdensome for patients.GlobeNewswire Inc. · Aug 13, 2024

Dare Bioscience regains Nasdaq compliance with bid price - Investing.comDare Bioscience, a biopharmaceutical company focused on women's health, has regained compliance with Nasdaq's minimum bid price requirement. The company's common stock achieved the necessary closing bid price of $1.00 or more per share over 10 consecutive trading sessions.Investing.com · Jul 19, 2024

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule - GlobeNewswireDaré Bioscience, a biopharmaceutical company focused on women's health, announced that it has regained compliance with the Nasdaq minimum bid price requirement. The company is advancing its pipeline of potential first-in-category product candidates, including Ovaprene, a hormone-free monthly contraceptive, and Sildenafil Cream for female sexual arousal disorder.GlobeNewswire Inc. · Jul 19, 2024

Daré Bioscience Announces Reverse Stock SplitShares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024GlobeNewswire Inc. · Jun 27, 2024

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1Daré Bioscience’s DARE-LARC1 Platform Technology has Transformative Potential for Women’s Health as well as in Treating a Broad Range of DiseasesGlobeNewswire Inc. · Apr 23, 2024

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 28, 2024, to review its financial results for the year ended December 31, 2023 and to provide a company update.GlobeNewswire Inc. · Mar 21, 2024

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024There are no FDA-approved treatments for female sexual arousal disorder There are no FDA-approved treatments for female sexual arousal disorderGlobeNewswire Inc. · Jan 31, 2024

Daré Bioscience Announces Executive Team and Board of Directors ChangesSAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the retirement of Chief Financial Officer, Lisa Walters-Hoffert, and the resignation of Chief Commercial Officer, John Fair. Both Ms. Walters-Hoffert and Mr. Fair have entered into plans with the Company to help ensure a seamless transition. Daré also announced an adjustment to the size of its Board of Directors to better reflect the Company’s size following the voluntary resignations of Cheryl R. Blanchard, Ph.D. and Sophia Ononye-Onyia, Ph.D.GlobeNewswire Inc. · Jan 26, 2024

to start trading

DA

DAREDare Bioscience, Inc. Common Stock

DARE

Pay with—

Available Balance0.00

Your PositionYou don't own any DARE yet.

Related Tickers

Earnings